JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

13.21 -2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.02

Massimo

13.56

Metriche Chiave

By Trading Economics

Entrata

13M

-72M

Vendite

18M

38M

Margine di Profitto

-189.28

Dipendenti

270

EBITDA

20M

-64M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+159.07% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

236M

1.1B

Apertura precedente

15.21

Chiusura precedente

13.21

Notizie sul Sentiment di mercato

By Acuity

66%

34%

335 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 ott 2025, 23:28 UTC

Azioni calde

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 ott 2025, 23:07 UTC

Utili

Prudential PLC 3Q New Business Profit Up 13%

30 ott 2025, 00:00 UTC

Utili

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 ott 2025, 00:00 UTC

Utili

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 ott 2025, 00:00 UTC

Utili

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 ott 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 ott 2025, 23:40 UTC

Utili

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 ott 2025, 23:38 UTC

Discorsi di Mercato

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 ott 2025, 23:25 UTC

Utili

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 ott 2025, 22:51 UTC

Utili

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 ott 2025, 22:45 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 ott 2025, 22:41 UTC

Utili

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 ott 2025, 22:41 UTC

Utili

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 ott 2025, 22:09 UTC

Utili

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 ott 2025, 22:08 UTC

Discorsi di Mercato
Utili

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 ott 2025, 21:58 UTC

Utili

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 ott 2025, 21:58 UTC

Utili

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 ott 2025, 21:57 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 ott 2025, 21:54 UTC

Utili

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 ott 2025, 21:46 UTC

Utili

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 ott 2025, 21:43 UTC

Utili

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 ott 2025, 21:43 UTC

Utili

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 ott 2025, 21:42 UTC

Utili

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 ott 2025, 21:42 UTC

Utili

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 ott 2025, 21:41 UTC

Utili

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 ott 2025, 21:41 UTC

Utili

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 ott 2025, 21:41 UTC

Utili

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 ott 2025, 21:41 UTC

Utili

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 ott 2025, 21:40 UTC

Utili

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 ott 2025, 21:39 UTC

Utili

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

159.07% in crescita

Previsioni per 12 mesi

Media 35 USD  159.07%

Alto 56 USD

Basso 17 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

11

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

335 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat